-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $11

Benzinga·11/12/2026 11:56:21
Listen to the news
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $12 to $11.